A press release reports that successful patient enrolment in the CE mark study of the next-generation JenaValve pericardial transcatheter aortic valve implantation (TAVI) system—using the Coronatix transfemoral delivery catheter—for the percutaneous treatment of severe aortic stenosis has been completed. The JenaValve pericardial TAVI system is an investigational device in the USA and internationally.
The JenaValve system is proprietary and differentiated from prior technologies, comprising the Everdur pericardial aortic valve with locator-based technology designed for more predictable implantation, combined with the new 18Fr compatible Coronatix transfemoral delivery catheter.
According to the press release, the optimised TAVI system has now been used to treat 10 patients across three sites in Germany and New Zealand. Technical success for those procedures was 100%, with no reported adverse events and no moderate or higher paravalvular leakage reported.
The CE mark study is an international, prospective, non-randomised, single-arm trial of the JenaValve pericardial TAVI system for the treatment of severe aortic stenosis in patients who are at increased risk for conventional surgical valve replacement.
The German national principal investigator, Hendrik Treede (Halle University, Halle, Germany), says: “The novel JenaValve transcatheter valve may address the ongoing clinical needs for these patients. Specifically, early experience with this innovative transcatheter heart valve demonstrates low permanent pacemaker rates, negligible mean pressure gradients across the valve and no significant paravalvular leaks. Additionally, the new transfemoral system enables rapid, safe, and reliable delivery of this new valve.”
Chief executive officer at JenaValve Victoria Carr-Brendel comments: “We were already extremely pleased with the initial clinical results of our next-generation TAVI valve, Everdur. Now, the most recent implants using the optimised delivery system have shown significantly improved ease of use and performance. We have invested a substantial amount of intellectual know-how, capital and time to develop the Everdur valve and Coronatix delivery catheter, and they are exceeding our expectations. We look forward to expanding our clinical development programmes and building on this initial body of clinical evidence to eventually improve results, quality of life and survival among patients with these very serious conditions.”
JenaValve expects to complete patient enrolment by mid-2018 at clinical sites in Germany, The Netherlands, New Zealand and the USA. It anticipates CE mark approval by the end of 2018.
